Apposite Capital
No summary available yet.
Apposite is that rare breed - a genuinely healthcare-obsessed fund that actually knows what it's talking about. Nearly half their LPs are committed to healthcare impact investing, and their portfolio companies have achieved 20%+ annual revenue and employment growth on average - which is solid execution, not just marketing fluff. The Ulthera exit to Merz for up to $600M shows they can deliver returns, and founders consistently praise their hands-on approach. They're small with a flat hierarchy and human touch - think boutique healthcare specialists, not spreadsheet jockeys. The downside? £5M-£20M check sizes and £200M under management means they're playing in a specific sandbox - great if you fit, limiting if you don't. They're genuinely impact-focused, which is refreshing, but also means they'll pass on profitable healthcare plays that don't move the needle on patient outcomes.
- —Best for: Healthcare SMEs needing £5-20M with genuine impact story
- —Known for: Hands-on support and healthcare sector expertise that founders rave about
- —Watch out for: Limited check sizes and rigid focus - if you're not core healthcare, look elsewhere
Apposite Capital are experienced private equity investors dedicated to the UK and European healthcare industry, focused on creating a positive healthcare impact. We achieve this by focusing on three core health impact objectives: improving quality, increasing access, and promoting innovation.
Their minimum investment size is 5 million, while the maximum can reach up to 20 million. Based in London, Apposite Capital prides itself on having strategic specialties in Expansion, Later Stage ventures, and Management Buyout/Management Buy-In (MBO/LBO) opportunities. Apposite Capital provides a mix of venture, development, and growth financing, along with buyout capital. They act as the first institutional capital to help healthcare SMEs scale and grow via management buyouts and buy-ins, growth and hybrid capital, retirement sales and founder transitions.
David Porter is Managing Partner and Founding Partner at Apposite Capital LLP, an investment firm exclusively focused on healthcare. He co-founded the firm in 2006 and has led the team's healthcare-focused strategy. He recently discussed the dynamic landscape of private equity investments in the healthcare sector, as well as the impact of technology, including AI, on healthcare investments.
Sam Gray serves as Managing Partner at Apposite Capital. Former CEO of Ulthera Inc praised: 'Had the pleasure of Apposite's Sam Gray being a member of the Wellpartner's Board of Directors for 5+ years. His help and guidance in turning the Company around and selling it to a strategic buyer was invaluable.' He is known for hands-on board involvement and operational guidance.
Rory Pope is a Partner at Apposite Capital. Listed among the core investment team but specific background details were not found in current sources.
Anne-Laure Meynier serves as Partner at Apposite and recently participated in healthcare M&A investment panels, discussing topics such as M&A integration and impact and trends in the current M&A market. She focuses on healthcare M&A investments and brings European market expertise.
Have a specific question about Apposite Capital?
Ask Bernie →